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ABSTRACT
Introduction: To review measles IgM-positive cases of febrile rash illnesses in the State of 
São Paulo, Brazil, over the five-year period following interruption of measles virus transmission. 
Methods: We reviewed 463 measles IgM-positive cases of febrile rash illness in the State of São 
Paulo, from 2000 to 2004. Individuals vaccinated against measles ≤ 56 days prior to specimen 
collection were considered to be exposed to the vaccine. Serum from the acute and convalescent 
phases was tested for evidence of measles, rubella, parvovirus B19 and human herpes virus-6 
infection. In the absence of seroconversion to measles immunoglobulin-G, measles IgM-positive 
cases were considered false positives in individuals with evidence of other viral infections. 
Results: Among the 463 individuals with febrile rash illness who tested positive for measles IgM 
antibodies during the period, 297 (64%) were classified as exposed to the vaccine. Among the 166 
cases that were not exposed to the vaccine, 109 (66%) were considered false positives based on 
the absence of seroconversion, among which 21 (13%) had evidence of rubella virus infection, 
49 (30%) parvovirus B19 and 28 (17%) human herpes virus-6 infection. Conclusions: Following 
the interruption of measles virus transmission, thorough investigation of measles IgM-positive 
cases is required, especially among cases not exposed to the vaccine. Laboratory testing for 
etiologies of febrile rash illness aids interpretation of these cases. 
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RESUMO
Introdução: Revisar os casos de doenças febris exantemáticas com IgM reagente contra o sarampo, 
no Estado de São Paulo, Brasil, durante os cinco anos seguidos a interrupção da transmissão do 
vírus do sarampo. Métodos: Nós revisamos 463 casos de doenças febris exantemáticas com IgM 
reagente contra o sarampo, no Estado de São Paulo, Brasil, de 2000 a 2004. Indivíduos vacinados 
contra o sarampo 56 dias antes da coleta de amostra foram considerados expostos à vacina. Soros 
da fase aguda e de convalescença foram testados para a evidência de infecção de sarampo, rubéola, 
parvovírus B19 e herpes vírus 6. Na ausência de soroconversão para imunoglobulina G contra 
o sarampo, casos com IgM reagente contra o sarampo foram considerados falsos positivos em 
pessoas com evidência de outras infecções virais. Resultados: Entre as 463 pessoas com doenças 
febris exantemáticas que testaram positivo para anticorpos IgM contra o sarampo durante o 
período, 297 (64%) pessoas foram classificadas como expostas à vacina. Entre os 166 casos 
não expostos à vacina, 109 (66%) foram considerados falsos positivos baseado na ausência de 
soroconversão, dos quais 21 (13%) tiveram evidência de infecção por vírus da rubéola, 49 (30%) 
parvovírus B19 e 28 (17%) infecção por herpes vírus humano 6. Conclusões: Após a interrupção 
da transmissão do vírus do sarampo é necessária exaustiva investigação dos casos com IgM 
reagente contra o sarampo, especialmente dos casos não expostos à vacina. Testes laboratoriais 
para etiologias das doenças febris exantemáticas ajudam na interpretação destes casos.
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Brazil interrupted endemic measles virus 
transmission in 20001. Measles elimination in Brazil 
followed the Pan-American Health Organization 
(PAHO) regional strategy2. High routine coverage 
and follow-up campaigns have continued since 2000 
to prevent sustained transmission of measles virus 
following importations1,3..
Brazil maintains surveillance for febrile rash 
illnesses through collection of acute phase blood 
samples for measles and rubella serological tests. 
As recommended by PAHO3,4, individuals with 
febrile rash illness and positive serological tests 
for measles immunoglobulin M (IgM) antibodies 
are treated as confirmed measles cases, for prompt 
implementation of control strategies. However, 
in the absence of measles virus transmission, 
individuals with febrile rash illnesses may test 
positive for IgM antibodies as a result of recent 
measles vaccination or cross-reactivity of serological 
assays with other etiologies of rash illness5. Guidance 
for interpretation of positive measles IgM in settings 
of little or no measles virus transmission has been 
published4-7, but there are few data from surveillance 
systems on the classification of measles IgM-positive 
reactions in practice. 
The objective of this study was to review the 
possible causes of measles IgM-seropositive episodes 
of febrile rash illnesses in the State of São Paulo, 
Brazil, following interruption of endemic measles 
virus transmission. 
METHODS
Study population
The State of São Paulo, Brazil, has approximately 
40 million inhabitants, with 18 million residents 
in São Paulo metropolitan area. Measles vaccine 
has been used since 1968. During 2000-2003, 
the recommended vaccination schedule included 
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RESULTS
monovalent measles vaccine at nine months of age and measles-
mumps-rubella (MMR) vaccine at 15 months of age. In 2003, the 
schedule included a single dose of MMR at 12 months of age. In 2004, 
a recommendation for a second dose of MMR among children 4 to 6 
years of age was added to the immunization calendar. Between 2000 
and 2004, approximately 700,000 doses of measles vaccines were 
administered annually in routine immunizations (greater than 95% 
vaccination coverage with a first dose of measles vaccine). In addition, 
in 2000 and 2004, more than 92% of children 1-4 years of age were 
vaccinated during statewide measles follow-up campaigns with over 5.2 
million children vaccinated. Mass vaccination of women of childbearing 
age was conducted in 2001, with over 4.4 million doses of measles-rubella 
(MR) vaccine administered (91% vaccination coverage).
Syndromic surveillance for febrile rash illness
Integrated measles/rubella surveillance has been conducted 
in the State of São Paulo since 1992. Notification of suspect cases 
of measles and rubella is mandatory, with immediate reporting to 
epidemiological surveillance officers in municipal and regional health 
departments. The surveillance case definition for suspected measles 
is a person presenting with fever, rash and either cough, coryza or 
conjunctivitis. For enhanced surveillance, the suspected measles case 
definition includes specific clinical symptoms: fever for more than two 
days prior to rash onset and presence of rash for at least three days. 
The case definition for suspected rubella is a person presenting with 
fever, rash and lymphadenopathy. Blood specimens for serological 
testing are collected at the first contact with suspected cases. The 
protocol requires investigation of suspected cases within 48 hours 
of the report. Surveillance officers collect clinical and laboratory 
information, interview case patients, complete notification forms, 
actively search for secondary cases and vaccinate close contacts. 
Immunization histories are recorded from vaccination cards; only 
documented doses of measles vaccines are recorded.
Measles IgM-seropositive episodes require additional case investigation 
and vaccination of contacts1,3. In 2001, enhanced surveillance to verify 
interruption of endemic measles transmission included collection 
of whole blood and urine for virus isolation from suspected measles 
cases with specific clinical symptoms  Beginning in 2002, investigation 
of measles IgM-positive episodes in vaccine-unexposed individuals 
included collection of a second blood specimen for comparison of measles 
immunoglobulin G (IgG) antibody titers in serum pairs. 
Laboratory methods
Measles and rubella serological tests were performed in nine 
regional laboratories of the Adolfo Lutz Institute. Measles IgM and 
IgG serological tests were performed using commercial indirect 
enzyme-linked immunosorbent assays (ELISA) (Dade Behring, 
Marburg, Germany) and/or measles IgM-capture ELISA (provided 
by the US Centers for Disease Control and Prevention [CDC])8,9. 
Measles IgG concentrations were standardized to International 
Units per ml using an internal reference, in accordance with the 
manufacturer’s instructions. Rubella IgM serological tests were 
performed using commercial ELISA kits (Dade Behring, Marburg, 
Germany) or IgM-capture ELISA (Rubenostika II, Organon Teknika, 
Boxtel, Netherlands). Rubella IgM-seronegative episodes were tested 
for measles IgM antibodies and vice versa10. Suspected cases that were 
negative for both measles and rubella IgM antibodies were discarded 
based on laboratory criteria. In measles IgM-positive samples, 
additional laboratory tests were conducted to investigate possible 
alternative etiologies of rash illness, especially in cases without recent 
vaccination. Samples were tested for human parvovirus B19 infection 
using a commercial IgM-capture ELISA (Biotrin, Dublin, Ireland) or 
the polymerase chain reaction (PCR)11 and for human herpesvirus-6 
infection using immunofluorescence (Biotrin, Dublin, Ireland) or 
PCR12. Testing for dengue virus (EIA, PanBio), Epstein-Barr virus 
(ELISA, Biomérieux, Boxtel, Netherlands) or varicella virus (ELISA, 
Dade Behring) was based on clinical suspicion. 
Classification of measles IgM-seropositive cases
Individuals vaccinated against measles ≤ 56 days prior to 
specimen collection were considered to be vaccine-exposed, regardless 
of the date of symptom onset13. Episodes for which serum pairs 
demonstrated no seroconversion (from measles IgG seronegative 
to IgG positive) were discarded as non-measles. Presence of rubella 
IgM antibodies in individuals without recent vaccination against 
rubella or with an epidemiological link to a confirmed rubella case 
were considered to be evidence of rubella virus infection. A positive 
PCR reaction or serological assay was considered to be evidence of 
parvovirus B19 or human herpesvirus-6 (HHV-6) infection.
Statistical analysis
Data were double-entered in the Epi-Info software (version 6.04d, 
Centers for Disease Control and Prevention, Atlanta, GA, USA) and 
analyzed using the Statistical Package for the Social Sciences (SPSS, release 
15, SPSS Inc, Chicago, IL, USA). The spatial and temporal distribution of 
measles IgM-positive cases was examined according to the epidemiological 
week of symptom onset and place of residence, in terms of the administrative 
district for the city of São Paulo or municipality and administrative health 
region (analogous to counties) for the rest of the state.
Ethical
This study was approved by the Ethics Research Committee of 
the School of Public Health of the University of São Paulo.
Between 2000 and 2004, 5,326 suspected measles cases and 
36,977 suspected rubella cases were notified to the State of São 
Paulo Health Department. Among these 42,303 notifications of 
suspected measles or rubella, the investigations began within two 
days of notification in 39,342 (93%) cases and within eight days 
of rash onset in 33,419 (79%) cases. The measles notification rate 
declined from 5.6 to 1.2 suspected episodes per 100,000 population 
over this five-year period, while the rubella notification rate declined 
from 31.4 per 100,000 during a rubella epidemic in 2000, to 11.6 per 
100,000 during 2003-2004 (Figure 1). 
From 2000-2004, serum specimens were tested in relation to 
38,913 (92%) of the 42,303 suspected measles or rubella episodes. 
There were 5,369 confirmed rubella episodes and 16 confirmed measles 
episodes (14 in 2000, one in 2001 and one in 2002). Of the confirmed 
measles episodes in 2000, 10 were laboratory-confirmed based on 
measles IgM antibodies in acute phase serum and were included in 
this analysis; of these, nine were vaccine-exposed. The confirmed 
measles cases in 2001 and 2002 were imported from Japan1. In 2001, 
the measles virus was not isolated from specimens in any of the 41 
suspected measles cases with specific clinical symptoms. From 2000-
2004, the annual rate of laboratory-discarded suspected measles cases 
averaged 2.5 episodes per 100,000 population (range 1.1 to 5.5). 
Among the 38,913 serum specimens tested, 463 episodes (1%) 
tested positive for measles-specific IgM antibody in the initial serum 
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FIgURE 1 - Rate of notifications of suspected measles and rubella cases per 100,000 population, 
State of São Paulo, 2000-2004.
FIgURE 2 - Notified rash illness episodes and anti-measles IgM seropositive episodes according to date of rash illness onset, State of São Paulo, 
2000–2004.
specimen and were included in this analysis; 99 (21%) were originally 
notified as suspected measles and 364 (79%) as suspected rubella. 
Blood specimens with measles IgM antibody were collected a median 
of two days after rash onset (range, 0 to 28 days). 
A second blood specimen was obtained from 228 (49%) of the 
463 case patients. The interval between the initial and follow-up 
specimens was at least 14 days for 171 (75%) of the 228 episodes 
(median, 21 days; range 4 to 178 days). In total, 55 (24%) of the 228 
episodes showed seroconversion in measles IgG antibodies; two 
episodes occurred in children without prior measles vaccination 
(one imported case of measles in 2000 and one child who received 
measles vaccine prior to collection of convalescent serum).
During the five-year period, the temporal distribution of measles 
IgM-positive cases showed seasonal variation, with peaks between 
September and November, corresponding to months with increased 
transmission of febrile rash illnesses (Figure 2). In addition, there 
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were two peaks of measles IgM-positive cases in 2001 and 2002 
following two imported cases of measles from Japan. During these 
two months, cases were identified in different geographical areas and 
10 (53%) of the 19 IgM-positive episodes in unvaccinated individuals 
tested positive for other viral illnesses. Extensive contact tracing did not 
identify any secondary cases associated with these importations.
While the majority (56%) of the measles IgM-positive episodes 
identified during 2000-2004 resided in the metropolitan region of São 
Paulo (which accounts for 48% of the state’s population), IgM-positive 
episodes were also identified in 120 of the 645 municipalities throughout 
the state, and were not clustered temporally in the same geographical area. 
In 25 (5%) of the 463 episodes, the patients identified epidemiological 
links to other individuals who had acute rash illnesses, but none of these 
contacts was positive for measles IgM antibodies.
Documentation of measles vaccination was available for 
389 (84%) of the 463 measles IgM-positive cases. In 297 cases, the 
patients were classified as vaccine-exposed, while 92 had received 
measles vaccine more than 56 days prior to sample collection. The 
vaccination history was unknown for 28 individuals, and 46 had not 
any prior measles vaccination (Table 1).
The age range of case patients in each measles vaccination history 
group was consistent with vaccine recommendations: 65% of the 
case patients with no prior measles vaccination were younger than 
12 months of age, 97% of case patients with recent vaccination were 
9-23 months old, and 92% of those with past measles vaccination 
were one year old or over (Table 1). Among measles IgM-positive 
case patients with no prior measles vaccination, 32% were 15 years 
TABLE 1 - Notified rash illness episodes with positive serological tests for measles IgM antibodies in the absence of documented measles virus transmission, 
according to measles vaccination history, State of São Paulo, Brazil,2000-2004. 
                                                                                           Vaccine-unexposed
  No prior  Prior  Unknown 
  measles  measles  measles 
 Vaccine-exposed* vaccination vaccination† vaccination
Characteristics and clinical symptoms n=297 n=46 n=92 n=28
 Measles IgM-positive  Number with characteristic or clinical symptoms (%)
Female gender 162 (55) 27 (59) 55 (60) 18 (64)
Age group     
< 9 months 3 (1) 25 (55) 0 (-) 0 (-)
9 to 11 months 156 (52) 5 (11) 7 (8) 1 (3)
12 to 23 months 133 (45) 0 (-) 16 (17) 3 (11)
2 to 4 years 2 (1) 1 (2) 20 (22) 0 (-)
5 to 14 years 0 (-) 0 (-) 26 (28) 3 (11)
15 to 29 years 3 (1) 8 (17) 16 (17) 16 (57)
>= 30 years 0 (-) 7 (15) 7 (8) 5 (18)
Suspected measles case‡ 179 (60) 32 (70) 48 (52) 13 (46)
Suspected measles case with specific clinical symptoms§  38 (13) 13 (28) 16 (17) 4 (14)
Rash 291 (98) 46 (100) 89 (97) 23 (82)
Days of rash, median (range)║ 3 (0-21) 4 (1-14) 4 (0-15) 3 (0-15)
Fever 260 (88) 43 (93) 72 (78) 20 (71)
Days of fever, median (range)║ 2 (0-20) 3 (0-30) 2 (0-15) 2 (0-19)
Cough 147 (49) 25 (54) 32 (35) 7 (25)
Conjunctivitis 44 (15) 11 (24) 17 (18) 8 (29)
Coryza 150 (51) 25 (54) 41 (45) 8 (29)
Lymphadenopathy 123 (41) 16 (35) 36 (39) 13 (46)
*vaccinated ≤ 56 days prior to specimen collection, †vaccinated > 56 days prior to specimen collection, ‡fever, rash and either cough, coryza or conjunctivitis, §suspected 
measles case with prolonged fever (> 2 days) prior to rash onset, and rash > 2 days duration, ║excluding individuals with no reported rash or fever.
of age or over. The age distribution of vaccine-exposed cases reflected 
the change in 2003 of the recommended age for measles vaccination 
from 9 to 12 months: prior to 2003, 52% of the vaccine-exposed 
cases occurred among children 9 to 11 months of age versus less 
than 1% after 2003.
According to the clinical data for the measles IgM-positive 
episodes of rash illness, only 59% of the episodes met the suspected 
measles case definition (presence of rash, fever and at least one 
respiratory symptom); the proportion was highest among case 
patients with no prior measles vaccination (Table 1). Only 15% 
of measles IgM-positive episodes met the more specific clinical 
symptoms of three or more days of rash with preceding fever, with 
the highest proportion among case patients with no prior vaccination. 
Four patients, aged four months, 10 months, 23 years and 47 years, 
were hospitalized; the admission diagnoses were dehydration, 
scarlatina, acute respiratory infection and pneumonia, respectively.
Among the 463 measles IgM-seropositive episodes, 211 (46%) 
had laboratory evidence of infection with other etiologies of rash 
illness (Table 2). Among the 166 vaccine-unexposed episodes, 
109 (66%) had evidence of another infection: 21 (13%) with rubella 
virus, 49 (29%) with parvovirus B19, 28 (17%) with HHV-6, five 
(3%) with dengue virus, five (3%) with Epstein Barr virus and 
one (1%) with varicella. In addition to measles IgM antibodies, 
27 individuals (6% of 463) were IgM-positive for both rubella and 
HHV-6, three (1%) for HHV-6 and parvovirus B19 and 12 (3%) 
for rubella and parvovirus B19. None of the episodes tested by PCR 
were positive for both parvovirus and HHV-6.
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TABLE 2 - Results from laboratory testing on initial serum specimens for measles, rubella and other viral etiologies of febrile rash illness, among measles IgM-
seropositive rash illness episodes reported to the measles/rubella surveillance system, State of São Paulo, Brazil, 2000-2004. 
Laboratory results 
Measles IgM-positive n=297 n=46 n=92 n=28                              n=463
                                number positive/number tested (%) 
Measles‡ 9/297 (3) 2/46 (4) 1/92 (1) 0/28 (-) 12/463 (3)
Indirect IgM ELISA 257/296 (87) 37/46 (80) 73/92 (79) 25/28 (90) 392/462 (85)
IgM-capture ELISA 228/287 (79) 20/46 (43) 32/90 (35) 10/28 (36) 290/451 (64)
Both indirect IgM and IgM-capture ELISA 193/286 (67) 12/46 (25) 18/91 (21) 7/28 (25) 230/451 (51)
IgG ELISA, seroconversion in paired specimens 51/117 (44) 2/32 (6) 2/63 (3) 0/16 (-) 55/228 (24)
Rubella‡ 4/223 (2) 9/41 (22) 2/86 (2) 10/27 (37) 25/377 (7)
Indirect IgM ELISA 50/112 (45) 1/12 (8) 1/33 (3) 2/6 (33) 54/163 (33)
IgM-capture ELISA 9/111 (8) 4/29 (14) 2/53 (4) 10/21 (48) 25/214 (12)
Parvovirus B19 35/169 (21) 7/32 (22) 37/80 (46) 5/18 (28) 84/299 (28)
IgM-capture ELISA 13/169 (8) 2/32 (6) 26/80 (33) 5/18 (28) 46/299 (15)
PCR (11) 23/109 (21) 5/15 (33) 24/61 (39) 3/13 (23) 55/198 (28)
HHV-6 63/179 (35) 9/36 (25) 13/80 (16) 6/18 (33) 91/313 (29)
Immunofluorescence (12) 59/179 (33) 9/36 (24) 12/80 (15) 8/18 (44) 88/313 (28)
PCR (12) 5/138 (4) 3/21 (14) 1/47 (2) 1/13 (8) 10/219 (5)
*vaccinated ≤ 56 days prior to specimen collection, †vaccinated > 56 days prior to specimen collection, ‡ totals for laboratory-confirmed measles and rubella episodes include 
only the episodes with a final classification as measles or rubella based on clinical and epidemiological criteria.
Vaccine-exposed*
Prior measles 
vaccination†
Unknown measles 
vaccination
No prior measles
 vaccination Total
DISCUSSION
Reviewing the measles IgM-seropositive rash illness episodes 
provided useful indicators for the sensitivity of the State of São 
Paulo measles surveillance system following the interruption of 
endemic measles virus transmission. The overall rate of measles-like 
illnesses discarded based on laboratory testing was similar to the rates 
reported from the United States and other countries in the Americas14. 
Approximately 1% of notified rash illness episodes tested positive for 
measles IgM antibodies. Active investigation of IgM-positive episodes 
demonstrated the importance of having a documented vaccination 
history and additional laboratory testing for case classification. Fewer 
than 32% of the episodes met all the criteria for classification as 
vaccine-associated or false-positive reactions5,6, mainly as a result of 
gaps in the vaccination history or poorly timed specimen collection. 
Close supervision with follow-up to obtain complete information 
resulted in better data quality for classification, considering that this 
is a passive surveillance system15. Regular review of IgM-seropositive 
episodes helped maintain a high level of alert for measles importations, 
to prevent reintroduction of the measles virus.
As expected based on the high MMR vaccination coverage 
and periodic follow-up campaigns, the majority of the positive 
IgM reactions occurred in recently vaccinated individuals. The age 
distribution of vaccine-exposed cases followed the recommended 
age of measles vaccination, and immunization campaigns focused 
on targeted groups. The measles IgM-positive episodes were not 
clustered geographically and temporally, thus providing evidence that 
measles transmission was absent during this period. Seasonal peaks of 
IgM-positive episodes coincided with the winter and spring months, 
when transmission of rubella, erythema infectiosum and other 
viral illnesses is highest (including measles in the pre-elimination 
era)16,17. None of the IgM-positive episodes had epidemiological 
links to the two imported measles cases identified during the period, 
despite extensive contact tracing1. Although we cannot rule out the 
possibility that individual cases were true measles infections, this 
review suggested that the surveillance system had adequate sensitivity 
for identifying measles transmission.
The main limitation of the State of São Paulo measles surveillance 
was the dependence on serological testing. Timely specimen collection 
and transportation to the central health department laboratory under 
appropriate conditions are needed for virus detection. Collection of 
serum and urine specimens for virus isolation is indicated for measles IgM 
seropositive episodes10, but this results in poorly timed sample collection 
and low rates of virus isolation18. Few specimens tested for measles virus 
were collected less than six days after rash onset. In the event of measles 
importation in such a highly vaccinated population, virus detection and 
characterization is essential for distinguishing wild-type measles infection 
from vaccine-associated rash illness18,19. Alternative diagnostic samples, 
including saliva, which can be collected on filter paper at the first contact 
with the healthcare system and later tested for measles virus RNA could 
improve the timeliness of specimen collection for virus detection20.
Without timely specimen collection for virus detection, true 
measles cases may have been missed. In a highly vaccinated population, 
individuals may present with clinical manifestations that are less 
characteristic of classic measles21,22, and such cases may not have been 
notified to the surveillance system. It has been recognized that clinical 
criteria cannot be used alone to rule out measles infection6. However, 
if measles virus transmission had been occurring, unvaccinated 
individuals and a small proportion of vaccinated individuals would 
have been expected to develop classical measles symptoms21,23. While 
individuals with asymptomatic or vaccine-modified measles may be 
less likely to infect others24,25, their role in sustaining low levels of 
measles virus transmission is unclear21,26,27.
The availability of additional laboratory testing supported the 
findings from the epidemiological investigation. In accordance 
with the established procedures of the regional measles laboratory 
network28, public health laboratories throughout the State of São 
Paulo used a single commercial indirect ELISA kit for measles 
serological assays. The state health department added a second 
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serological assay, the IgM-capture ELISA, at the state reference 
laboratory to aid in the interpretation of positive measles IgM serology. 
Both tests have high specificity6,8 but may differ in their cross-reactivity 
with other viral causes of rash illness, including rubella, parvovirus and 
HHV-629. Use of the IgM-capture ELISA test may reduce false-positive 
results caused by rheumatoid factor8,9. However, concordant results from 
the two tests were not considered confirmatory. Measles IgG avidity 
testing on the initial samples may also be helpful for ruling out measles18. 
In addition, collection of a second blood specimen to compare measles 
IgG titers in serum pairs was useful for discarding episodes as non-
measles, although 51% of the serum pairs had an indeterminate result, 
with IgG titers increasing by less than fourfold. Testing for parvovirus 
B19 and HHV-6 infection, which are two common causes of rash illness, 
facilitated the classification of measles IgM-positive episodes. Cross-
reactivity of measles serological assays with parvovirus B19 and HHV-6 
infections has been described29. Additional laboratory testing (IgM EIA) 
on individual episodes identified the dengue virus, Epstein-Barr virus or 
varicella infection as other potential causes of measles IgM reactivity.
During 2000-2007, significant progress was made towards reducing 
measles morbidity and mortality worldwide30.  As long as measles 
circulates, Brazil remains at risk of importations. Brazil receives more 
than five million visitors from other countries and more than one million 
Brazilians travel internationally, each year31. Notably, in 2008, Brazil 
remained free from importation-associated measles outbreaks that affected 
other countries32,33. However, the surveillance system needs to be prepared 
to rapidly identify and respond to imported measles, in order to limit its 
spread. Improvements in early specimen collection for virus isolation 
are needed, so that possible sources of imported cases can be identified. 
Maintaining political will in the absence of disease transmission requires 
a high level of confidence in the surveillance system. 
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